Login to Your Account

Other News To Note

Friday, May 4, 2012

• Exelixis Inc., of South San Francisco, expanded its cabozantinib development program under a cooperative research and development agreement with the National Cancer Institute's Cancer Therapy Evaluation Program.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription